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Abstract
S-(1,2-dichlorovinyl)-L-cysteine (DCVC) is 
known to cause renal-cellular injury after met-
abolic activation by cysteine conjugate β-lyase 
and to exert in vitro toxicity against bone-relat-
ed cell lines. However, little is known about the 
in vivo disposition of DCVC in mice.
We studied the in vivo disposition of [35S]
DCVC in mice after intraperitoneal adminis-
tration at a dose of 30  mg/kg. DCVC and its 
related substances were well absorbed rapid-
ly, distributed highly in the kidneys, and then 
slowly eliminated from the body. The concen-
tration of DCVC and its related substances was 
the highest in the femoral epiphysis in the bone 
tissues examined. The main excretion route was 
the urine. 
Introduction
Trichloroethylene (TCE) is generally used 
as synthetic material for alternative fluorocar-
bon or metal-degreasing agent. It is designated 
as a Class II Specified Chemical Substance, and 
required to be controlled under the guideline 
for environment conservation. Several studies 
revealed TCE toxicity in mice, rats and hu-
mans. 1), 2) TCE is metabolized in several path-
ways including glutathione (GSH)-dependent 
metabolism through which TCE is metabolized 
into DCVC 3). DCVC is considered to produce 
renal-cellular injury after metabolic activation 
by cystaine conjugate β-lyase 3). In mice, toxic-
ity of DCVC against cultured bone cells such 
as chondrocytes, osteoblasts and osteoclasts in 
vitro  4), decrease in bone density in vivo  5) and 
nephrotoxic effect of subchronic in mice 6) are 
reported. However, little is known about the in 
vivo disposition and distribution into the bone 
tissues of DCVC in mice. 
Objective
The concentration-time profiles of DCVC- 
related substances in blood, the excretion of 
DCVC-related substances in urine and feces, 
and the distribution of DCVC-related sub-
stances in tissues, especially the distribution 
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into the bone tissues, were investigated after 
single intraperitoneal administration of [35S]










A portion of [35S]DCVC (Radiochemical 
purity: 98.6%) was suspended in physiological 
saline to prepare a dosing formulation at a con-
centration of 6 mg/2.42 MBq/mL. The dosing 
formulation was administered intraperitoneally 
to non-fasted male Balb/c mice at 6  weeks of 
age (Charles River Laboratories Japan, Inc.) at 
a dose of 30  mg/kg. The blood was collected 
at 0.25, 0.5, 1, 2, 4, 8, 24 and 48 h. The urine 
and feces were collected at 0-24 and 24-48  h. 
The tissues were collected at 24 h. The samples 
were measured for radioactivity by liquid scin-
tillation counting after dissolution with SOLU-
ENE®-350. The concentration of radioactivity 
in the blood and tissues (µg  equiv./g or mL) 
and the excretion ratio in urine and feces (% of 
dose) were calculated.
Results and Discussion
1. Concentration-time profile of radioactivity 
in blood
After single intraperitoneal administration 
of [35S]DCVC at a dose of 30 mg/kg to non-fast-
ed male mice, the blood concentration of ra-
dioactivity reached Cmax (12.2 µg equiv./mL) at 
0.5 h and decreased to 6.3 µg equiv./mL by 24 h, 
followed by a decreased to 3.8 µg equiv./mL by 
48 h with t1/2* of 36.2 h (Figure 1).
*: Time points used for the calculation of t1/2 value 
were 8 to 48 h.
2. Distribution of radioactivity in the tissues
In the tissues at 24 h after administration, 
the concentration of radioactivity was the high-
est in the kidneys (154.7  µg equiv./g, tissue/
plasma ratio: 17.7). The concentrations were, 
in descending order, higher in the pancreas, liv-
er, stomach, femoral epiphysis and heart (from 
32.6 to 10.0  µg equiv./g) than in the plasma 
(8.9 µg equiv./mL) (Figure 2).
The concentrations in the other tissues were 
8.1 µg eq./g or mL or less. In the bone tissues, 
the concentration of radioactivity was the high-
est in the femoral epiphysis (10.0 µg equiv./g). 
The concentrations in the parietal, vertebra and 
femoral diaphysis were 4.1, 5.7 and 4.7 µg equiv-
./g, respectively. (Figure 3)
Figure 1 
Concentration of radioactiv-
ity in the blood of male mice after 
single intraperitoneal administra-
tion of [35S]DCVC at a dose of 
30 mg/12.1 MBq/kg. 
Each point with a vertical line 
represents the mean and SD for 
three animals.   
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3. Urinary and fecal excretion
The cumulative excretion ratios of the ra-
dioactivity into the urine and feces by 48  h 
after intraperitoneal administration were 
50.7% ± 6.2% and 6.9% ± 6.0% to the dose, re-
spectively, and the sum of the cumulative excre-
tion ratios was 57.6% ± 11.9% (Table 1).
These results indicated that DCVC and its 
related substances were well absorbed at a rela-
tively fast rate, and then slowly eliminated from 
the blood after intraperitoneal administration 
of [35S]DCVC to mice. DCVC and its related 
substances were mainly excreted into the urine. 
Figure 2 
Concentration of radio-
activity in the tissues of male 
mice after single intraperitoneal 
administration of [35S]DCVC at 
a dose of 30 mg/12.1 MBq/kg.
Each value and vertical line 
represents the mean and SD for 
three animals. 
Figure 3 
Concentration of radioactivity in the 
bones of male mice after single intraperito-
neal administration of [35S]DCVC at a dose 
of 30 mg/12.1 MBq/kg.
Each value and vertical line represents 
the mean and SD for three animals. 
Table 1
Cumulative excretion of radioactivity in the 
urine and feces of male mice after single intraper-
itoneal administration of [35S]DCVC at a dose of 
30 mg/12.1 MBq/kg. 
Each value represents the mean and SD for three 
animals.
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DCVC and its related substances were distrib-
uted widely into the tissues especially highly in 
the kidneys. In the several bone tissues exam-
ined, the concentration in the femoral epiphysis 
was approximately two times the concentration 
in each of the other bone tissues.
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